{"filings":[{"id":668036,"accession_number":"0001193125-26-239362","cik":2096997,"company_name":"Kailera Therapeutics, Inc.","ticker":"KLRA","form_type":"8-K","filed_at":"2026-05-26T20:18:46+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kailera Q1 net loss $78.9M; advances obesity pipeline with Phase 3 start and positive data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $78.9M in Q1 2026 vs $18.0M in Q1 2025; R&D expenses rose to $70.9M from $10.1M.","Cash $581.9M plus IPO proceeds of $718.8M expected to fund operations into mid-2028.","Initiated global Phase 3 KaiNETIC program for ribupatide injection; data expected 2028.","Positive Phase 2 oral ribupatide data: mean weight loss up to 12.1% at week 26; Phase 3 trials planned for early 2027.","Positive Phase 1 data for KAI-4729 tri-agonist: up to 16.0% weight loss at 12 weeks; Phase 1 outside China planned 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2867934777.3500004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97690,"accession_number":"0001193125-26-164040","cik":2096997,"company_name":"Kailera Therapeutics, Inc.","ticker":"KLRA","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Kailera Therapeutics closes IPO raising $718.8M; issues 44.9M shares at $16.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed IPO of 44,921,875 shares at $16.00 per share, including full exercise of underwriters' option for 5,859,375 additional shares.","Gross proceeds of $718.8 million before underwriting discounts and offering expenses.","Amended certificate of incorporation: authorized 800M shares of common stock and 10M shares of undesignated preferred stock.","Adopted classified board with staggered three-year terms; directors removable only for cause with two-thirds vote.","Amended bylaws to require advance notice for stockholder proposals and director nominations, and limit action by written consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2867934777.3500004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}